Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer
Laura Fugazzola, Rossella Elisei, Dagmar Führer, et al.
European Thyroid Journal (2019) Vol. 8, Iss. 5, pp. 227-245
Open Access | Times Cited: 240

Showing 1-25 of 240 citing articles:

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
Marcia S. Brose, Bruce Robinson, Steven I. Sherman, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 8, pp. 1126-1138
Closed Access | Times Cited: 181
Thyroid Cancer
Laura Boucai, Mark Zafereo, Maria E. Cabanillas
JAMA (2024) Vol. 331, Iss. 5, pp. 425-425
Closed Access | Times Cited: 175
The 5th edition of WHO classification of tumors of endocrine organs: changes in the diagnosis of follicular-derived thyroid carcinoma
Fulvio Basolo, Elisabetta Macerola, Anello Marcello Poma, et al.
Endocrine (2023) Vol. 80, Iss. 3, pp. 470-476
Open Access | Times Cited: 62
Long-Term Follow-Up Results of Ultrasound-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: More Than 5-Year Follow-Up for 84 Tumors
Se Jin Cho, Sun Mi Baek, Hyun Kyung Lim, et al.
Thyroid (2020) Vol. 30, Iss. 12, pp. 1745-1751
Closed Access | Times Cited: 109
Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era
Jaume Capdevila, Ahmad Awada, Dagmar Führer‐Sakel, et al.
Cancer Treatment Reviews (2022) Vol. 106, pp. 102380-102380
Open Access | Times Cited: 49
Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study
Manuel Weber, David Kersting, Burkhard Riemann, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 19, pp. 4194-4202
Open Access | Times Cited: 47
Differentiated thyroid carcinoma: An update
Pepijn van Houten, Romana T. Netea‐Maier, Johannes W. A. Smit
Best Practice & Research Clinical Endocrinology & Metabolism (2022) Vol. 37, Iss. 1, pp. 101687-101687
Open Access | Times Cited: 45
Diagnosis and treatment of thyroid cancer in adult patients — Recommendations of Polish Scientific Societies and the National Oncological Strategy. 2022 Update [Diagnostyka i leczenie raka tarczycy u chorych dorosłych — Rekomendacje Polskich Towarzystw Naukowych oraz Narodowej Strategii Onkologicznej. Aktualizacja na rok 2022]
Barbara Jarząb, Marek Dedecjus, Andrzej Lewiński, et al.
Endokrynologia Polska (2022) Vol. 73, Iss. 2, pp. 173-300
Open Access | Times Cited: 40
MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data
Louis Schubert, Mohamed Lamine Mariko, Jérôme Clerc, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 710-710
Open Access | Times Cited: 29
TERT accelerates BRAF mutant–induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis
Pengcheng Yu, Ning Qu, Rui Zhu, et al.
Science Advances (2023) Vol. 9, Iss. 35
Open Access | Times Cited: 24
Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance
Sarah Hamidi, Marie‐Claude Hofmann, Priyanka Iyer, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 23
The role of the hypothalamic–pituitary–thyroid axis in thyroid cancer
Laura Abaandou, Raisa Ghosh, Joanna Kłubo-Gwieździńska
The Lancet Diabetes & Endocrinology (2025)
Closed Access | Times Cited: 1
Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues
Alice Nervo, Alberto Ragni, Francesca Retta, et al.
Journal of Endocrinological Investigation (2020) Vol. 44, Iss. 3, pp. 403-419
Open Access | Times Cited: 54
Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study
Mijin Kim, Meihua Jin, Min Ji Jeon, et al.
Thyroid (2022) Vol. 33, Iss. 1, pp. 91-99
Closed Access | Times Cited: 32
Potential Role of PSMA-Targeted PET in Thyroid Malignant Disease: A Systematic Review
Alessio Rizzo, Manuela Racca, Sara Dall’Armellina, et al.
Diagnostics (2023) Vol. 13, Iss. 3, pp. 564-564
Open Access | Times Cited: 21
Annotation-Free Deep Learning-Based Prediction of Thyroid Molecular Cancer Biomarker BRAF (V600E) from Cytological Slides
Ching‐Wei Wang, Hikam Muzakky, Yu‐Ching Lee, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2521-2521
Open Access | Times Cited: 18
Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management
Özgür Mete, Andrée Boucher, Kasmintan A. Schrader, et al.
Endocrine Pathology (2024)
Open Access | Times Cited: 7
How [18F]FDG-PET/CT Affects the Management of Patients with Differentiated Thyroid Carcinoma in Clinical Routines
Jonas Vogel, Julia Sekler, Brigitte Gückel, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 588-588
Open Access | Times Cited: 6
Intratumoral Genetic Heterogeneity in Papillary Thyroid Cancer: Occurrence and Clinical Significance
Laura Fugazzola, Marina Muzza, Gabriele Pogliaghi, et al.
Cancers (2020) Vol. 12, Iss. 2, pp. 383-383
Open Access | Times Cited: 47
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients
Sébastien Perreault, Rose Chami, Rebecca Deyell, et al.
Current Oncology (2021) Vol. 28, Iss. 1, pp. 346-366
Open Access | Times Cited: 34
Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit
Lori J. Wirth, Cosimo Durante, Duncan J. Topliss, et al.
The Oncologist (2022) Vol. 27, Iss. 7, pp. 565-572
Open Access | Times Cited: 26
Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers
X. Lucy, Osvaldo Espin‐Garcia, Philippe L. Bédard, et al.
Thyroid (2022) Vol. 32, Iss. 6, pp. 657-666
Closed Access | Times Cited: 24
Advanced RAI-refractory thyroid cancer: an update on treatment perspectives
Olga Karapanou, George Simeakis, Barbara Vlassopoulou, et al.
Endocrine Related Cancer (2022) Vol. 29, Iss. 5, pp. R57-R66
Open Access | Times Cited: 24
Molecular features of aggressive thyroid cancer
Giusy Elia, Armando Patrizio, Francesca Ragusa, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 23
Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review
Hina Shah, Evan Ruppell, Rozan Bokhari, et al.
European Journal of Radiology Open (2023) Vol. 10, pp. 100477-100477
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top